Establishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will be added as a member of the US small-cap Russell 2000® Index, effective when the US market opens on June 29th as part of the 2026 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for half a year beginning 2026, is based on membershi.

Business Wire • Jun 25, 2026

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. “Route 92 Medical has built a strong position in neurovascular intervention,” said Raj Denhoy, CFO at Route 92 Medical.

GlobeNewsWire • May 18, 2026

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Establishment Labs Reports First Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United State.

Business Wire • May 6, 2026

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.

Zacks Investment Research • May 6, 2026

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quarter earnings this week.

Reuters • May 4, 2026

Establishment Labs® Refinances Credit Facility

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The amended and restated facility refinances the company's existing debt and allows access to additional capital to support ongoi.

Business Wire • Apr 30, 2026

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Cana.

Business Wire • Apr 23, 2026

Establishment Labs Insider Sells 37,500 Shares as Stock Jumps 128% in a Year

37,500 shares were sold indirectly for a total transaction value of approximately $2.45 million on April 14, 2026. All shares sold were indirectly held via Sariel Group Ltd, with no direct shares sold; after the trade, the insider retains 45,193 direct shares and 1,182,504 indirect shares, per the Form 4.

The Motley Fool • Apr 21, 2026

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction.

Business Wire • Apr 7, 2026